Results 11 to 20 of about 1,396,034 (289)
Adrenocortical carcinoma: Pediatric aspects (Review).
Experimental and Therapeutic Medicine, 2022 Adrenocortical carcinoma (adrenal cortex-derived cancer), an orphan malignancy, is a very aggressive disease that affects both adults and children with an annual incidence of 1-2 adult and 0.2-0.38 pediatric cases/million (in the pediatric population it ...
F. Șandru +5 more
semanticscholar +1 more source
Adrenocortical Carcinoma [PDF]
Endocrine Reviews, 2013 AbstractAdrenocortical carcinoma (ACC) is a rare endocrine malignancy, often with an unfavorable prognosis. Here we summarize the knowledge about diagnosis, epidemiology, pathophysiology, and therapy of ACC. Over recent years, multidisciplinary clinics have formed and the first international treatment trials have been conducted.
Tobias, Else +9 more
openaire +2 more sources
Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R [PDF]
, 2013 Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine neoplasm, with limited therapeutic options. Activating β-catenin somatic mutations are found in ACC and have been associated with a poor clinical outcome. In fact, activation of the
Bertherat, Jérôme +11 more
core +13 more sources
Adrenocortical carcinoma with inferior vena cava tumor thrombus found during surgery
IJU Case Reports, 2022 Introduction The safety and efficacy of minimally invasive approaches for adrenocortical carcinoma with inferior vena cava tumor thrombus have not yet been established.
Yuta Nabeshima +9 more
doaj +1 more source
Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat. [PDF]
Br J Clin PharmacolMitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
van Ton AMP +4 more
europepmc +2 more sources
Adrenocortical Carcinoma in Childhood: A Systematic Review
Cancers, 2021 Simple Summary Pediatric adrenocortical tumors are rare. Little information is available on the incidence, risk factors, prognostic factors, treatment, and overall survival. In this systematic review, we performed a search of the current literature.
Maria Riedmeier +11 more
semanticscholar +1 more source
Biomedicines, 2021 Adrenocortical carcinoma (ACC) is a rare endocrine malignancy arising from the adrenal cortex often with unexpected biological behavior. It can occur at any age, with two peaks of incidence: in the first and between fifth and seventh decades of life ...
Maja Mizdrak +2 more
semanticscholar +1 more source
Oncoimmunology, 2021 Background: Adrenocortical carcinoma is a rare malignancy, with poor prognosis and limited treatment options for patients with advanced disease. Chemotherapy is the current standard first-line treatment, providing only a modest survival benefit. There is
O. Klein +10 more
semanticscholar +1 more source
Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
Cancers, 2021 Simple Summary Adrenocortical carcinoma is a rare but aggressive malignancy with poor outcomes even for patients with early-stage disease. Several immunotherapy clinical trials, many of which are still in progress, have yielded modest results so far.
N. Georgantzoglou +3 more
semanticscholar +1 more source
GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo [PDF]
, 2015 We have previously demonstrated that estrogen receptor (ER) alpha (ESR1) increases proliferation of adrenocortical carcinoma (ACC) through both an estrogen-dependent and -independent (induced by IGF-II/IGF1R pathways) manner.
Amendola, Donatella +16 more
core +9 more sources